A novel therapeutic strategy exploiting cancer's Achilles heel: inability to survive without active DNA repair mechanisms.
A novel therapeutic strategy exploiting cancer's Achilles heel: inability to survive without active DNA repair mechanisms.
We've developed a sophisticated in-silico pipeline using generative AI to create novel molecules. This platform supports both target-based and phenotypic drug discovery approaches, ensuring generated molecules have optimal chemical properties.
Our molecules are optimized for potency, selectivity, and drug-like characteristics, reducing the need for high-throughput screening and significantly cutting experimental cycles, cost, and development time.
We are building a new class of cancer therapeutics based on synthetic lethality in the DNA damage response pathway. Instead of inducing more DNA damage, like chemotherapy or radiotherapy, we prevent the repair of naturally occurring DNA lesions in cancer cells.
Current cancer therapies indiscriminately damage DNA, affecting both healthy and cancerous cells. Tumours adapt by up-regulating DNA repair pathways, leading to resistance. Combination therapy that we are developing blocks cancer cells' DNA repair ability, preventing the survival of cancer cells.
Cancer cells have high levels of spontaneous DNA damage due to rapid proliferation and genomic instability. Normal cells have low DNA damage because they divide infrequently and maintain genomic stability. Rather than adding more DNA damage, we target the cancer cells' DNA repair pathways.
Our innovative strategy creates a therapeutic window where cancer cells are selectively killed, while healthy tissues are spared, offering a more precise and less damaging treatment alternative.
Extensive experience in pharmacology and drug discovery, designed the platform we use.
Molecular biologist with >10 years of hands-on experience from world-class institutions.
Senior research scientist with a veterinary background, plus 10 years of experience in executive leadership.
